A Phase II Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 04 Jun 2019 Results (n=96) resented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Results (n=27) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 06 Feb 2018 Study protocol amended with addition of third treatment arm which includes apatinib dose as 375mg/d (SHR-1210 200mg,q2w plus apatinib 375mg/d).